Skip to main content

Table 2 Hormonal and genetic data of patients

From: Extensive clinical, hormonal and genetic screening in a large consecutive series of 46,XY neonates and infants with atypical sexual development

Code

FSH (U/l)# (ref)

AMH ( μ g/l) (ref)$

T (ng/dl)*/**

AR

NR5A1

WT1

SRY

Array-CGH

MLPA

Other

1

3.2(1–12)

59.8(46.8-173)

136*

Nl

Nl

Nl

FISH Nl

Nl

Nl

HSD17B3

2

14.0(1–12)

62.7(46.8-173)

63.8*/579**

/

Nl

Nl

Nl

Nl

Nl

HSD17B3, ATRX N

3

6.6(1–12)

10.8(105–270)

4.7*

/

c.253_254del

/

Nl

/

/

 

4

1.6(1–12)

118(46.8-173)

195*

Nl

Nl

Nl

/

Nl

Nl

 

5

NA

152(67.4-197)

526**

Nl

c.437G > C (tolerated)

/

FISH Nl

/

/

 

6

3.3(1–12)

64.5(62–130)

184*

Nl

c.630_637del

/

FISH Nl

/

Nl

 

7

1.5(1–12)

57.6(105–270)

222*

Nl

Nl

Nl

/

7q36.3q36.3 (158189154–158343770)×1, maternal

Nl

 

8

NA

10.6(38–180)

275**

Nl

Nl

Nl

Nl

Nl

Nl

 

9

NA

231(46.8-173)

NA

Nl

Nl

Nl

/

Xp22.33p22.33 (839417–1179089)×3, maternal

Nl

 

10

NA

244(46.8-173)

NA

Nl

Nl

Nl

/

Nl

Nl

ATRX Nl

11

5.5(1–12)

NA

158*/511**

/

/

/

/

3p25(RP11-385A18 → RP11-334 L22)×3, 9p24.3 (RP11-48 M17 → RP11-320E16)×1

/

 

12

2.5(1–12)

147(46 · 8-173)

109*

/

Nl

Nl

/

/

Nl

 

13

NA

72.7(46.8-173)

280*

/

Nl

Nl

FISH Nl

Nl

Nl

 

14

1.2(1–12)

8.6(105–270)

248*

Nl

/

/

/

/

/

 

15

NA

132.9(42–185)

NA

Nl

c.1109 G > A (p Cys370Tyr)

/

FISH Nl

16p12.3p12.3 (18894303–19162153)×3,maternal (normal variant)

/

 

16

1.3(1–12)

298(67.4-197)

337*

Nl

Nl

Nl

FISH Nl

Xq13.3q13.3 (74285912–75325119)×2, maternal

Nl

 

17

NA

72(38–180)

NA

/

Nl

Nl

FISH Nl

/

Nl

HSD17B3

18

2.6(1–12)

82.2(23.8-124)

NA

Nl

Nl

Nl

/

2p16.3p16.3 (5073244–50894316)x1; 16p13.11p13.11(15830681–16270149)x3

Nl

 

19

1.8

49.1(23.8-124)

35.3*/390**

Nl

Nl

Nl

FISH Nl

Xq13.3q13.3(74380482–74567915)×2, maternal

Nl

 

20

2.8(1–12)

194(105–270)

104*

Nl

Nl

Nl

FISH Nl

Nl

Nl

 

21

1.9(1–12)

28.8(55.3-187)

NA

Nl

Nl

Nl

Nl

/

Nl

 

22

2.1(1–12)

94.1(105–270)

151*

Nl

Nl

Nl

Nl

5p14.3p14.3(21438696–21490654)×1, maternal, 14q21.2q21.3(42908541–43293564)×3, maternal

Nl

 

23

NA

11.27(55.3-187)

404**

Nl

Nl

Nl

Nl

Nl

Nl

 

24

NA

43(105–270)

152*/474**

/

Nl

Nl

Nl

Nl

Nl

SRD5A2 N

25

1.0(1–12)

156(105–270)

207.3*

Nl

Nl

Nl

/

Nl

Nl

 

26

0.17(1–12)

65.9(105–270)

3.3*/90.8 **

/

/

/

/

Nl

/

 

27

NA

245(55.3-187)

951**

Nl

Nl

Nl

/

/

Nl

 

28

NA

14.03(55.3-187)

NA

/

/

/

/

Xp22.32p22.31(5405569–9222059)×0, maternal

/

 

29

0.57(1–12)

NA

3.2*

/

/

/

/

/

/

FGFR1 c.1042G > A

30

1.2(1–12)

159(105–270)

502*

/

/

/

/

Nl

/

ZEB2 c.2856delG

32

11(1–12)

25(105–270)

191.9*

Nl

Nl

Nl

Nl

Nl

Nl

 
  1. Symbols and abbreviations: NA not available, FSH follicle stimulating hormone, AMH anti-Müllerian hormone, ref age-specific reference value, T testosterone, Nl, normal.
  2. # Determined between day 14–90; $: age-specific AMH reference values may differ according to the commercial kits that have been used during the course of the study; *Basal testosterone value between day 14–90/**: Testosterone value after HCG stimulation (1500 U, blood sampling after 72 h).
  3. Genomic coordinates based on build hg18 (2006), except for patient 32, where build hg19 (2009) is used.